A preplanned exploratory analysis from the MYSTIC trial showed an OS benefit in patients with PTMB > 16 mutations/Mbp in front-line combined anti-PD-L1 and anti-CTLA4 immunotherapy for advanced NSCLC (31). This evidence concerns the gene CTLA4 and non-small cell lung carcinoma.